Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard Noring is active.

Publication


Featured researches published by Richard Noring.


The New England Journal of Medicine | 1990

An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 Immunotherapy

Mark S. Klempner; Richard Noring; Michael B. Atkins

Bacterial sepsis is a frequent complication in patients with cancer who are receiving high doses of interleukin-2. We evaluated the function of neutrophils from such patients to determine whether there was any abnormality in this form of host defense. Before interleukin-2 therapy, neutrophils from 31 patients with metastatic cancer were normal in assays of random migration and chemotaxis. Superoxide production, phagocytosis, secretion of granule proteins, and bactericidal activity were also normal. Neutrophils from the patients near the end of the first course of interleukin-2 had severely impaired chemotaxis in response to a formylated peptide stimulus (mean [+/- SEM], 49.6 +/- 7.4 percent of base line; P less than 0.001). The detect in chemotaxis improved 5 to 10 days after patients completed the first course of interleukin-2 therapy but recurred toward the end of the second course of such therapy (35.3 +/- 6.9 percent of base line; P less than 0.001). The chemotactic response to a second stimulus (zymosan-activated serum) was also abnormal, but random migration, superoxide production, bactericidal activity, and the secretion of neutrophil granule constituents remained normal or increased throughout treatment with interleukin-2. We conclude that patients who receive interleukin-2 immunotherapy acquire an acute, profound, and reversible defect in neutrophil chemotaxis that may contribute to the high morbidity resulting from bacterial infections in these patients.


Journal of Bacteriology | 2004

Analysis of Differences in the Functional Properties of the Substrate Binding Proteins of the Borrelia burgdorferi Oligopeptide Permease (opp) Operon

Xing-Guo Wang; J. Michael Kidder; Joanna P. Scagliotti; Mark S. Klempner; Richard Noring; Linden T. Hu

The Borrelia burgdorferi genome encodes five orthologues of the substrate binding protein oligopeptide permease A (OppA). It was previously shown that these genes are under the control of separate promoters and are differentially expressed under various environmental conditions. We were interested in determining whether there are also differences in substrate specificities among the proteins. The substrate specificities of recombinant proteins were determined by screening for high-affinity peptides by use of a combinatorial phage display heptapeptide library. Different heptapeptides with high affinities for OppA-1, OppA-2, and OppA-3 were identified. No heptapeptide binding OppA-4 or OppA-5 could be identified. Competitive binding assays were performed under various conditions to determine the substrate preferences of the OppA proteins. OppA-1 retained maximal activity over a broad range of pHs (5.5 to 7.5), whereas OppA-2 and OppA-3 showed peak activities at pHs below 5.5. OppA-1 and OppA-2 showed preferences for tripeptides over dipeptides and longer-chain peptides. Although a wide variety of amino acyl side chains were tolerated by all three OppA proteins, OppA-1 showed the broadest substrate specificity and was able to accommodate peptides composed of bulky hydrophobic residues; OppA-2 and OppA-3 showed preferences for peptides composed of small nonpolar amino acids. All three OppA proteins showed preferences for peptides composed of L- rather than D-amino acids. OppA-3 showed the greatest tolerance for changes in stereochemistry. Substantial differences in the substrate specificities of the OppA proteins of B. burgdorferi suggest that they may have distinct functions in the organism.


The Journal of Infectious Diseases | 2001

Differences in Synovial Fluid Levels of Matrix Metalloproteinases Suggest Separate Mechanisms of Pathogenesis in Lyme Arthritis before and after Antibiotic Treatment

Bo Lin; J. Michael Kidder; Richard Noring; Allen C. Steere; Mark S. Klempner; Linden T. Hu

The cause of persistent arthritis in patients with Lyme disease who have received standard antibiotic therapy remains an area of debate. In this study, synovial fluid levels of matrix metalloproteinases (MMPs) were compared in persons with untreated and antibiotic-resistant Lyme arthritis. Levels of MMP-1 and MMP-3, as determined by ELISA, were higher in untreated patients (P=.0064 and P=.002, respectively), whereas levels of MMP-8 and MMP-9 were higher in antibiotic-resistant patients (P=.0002 and P=.0014, respectively). In vitro studies of chondrocyte cultures infected with Borrelia burgdorferi revealed induction of MMP-1 and MMP-3 but not of MMP-8 or MMP-9. Neither Staphylococcus aureus nor lipopolysaccharide stimulated MMP-1 or MMP-3 release from these cells. The mechanism of recognition of B. burgdorferi may be through CD14 and toll-like receptor-2, which were up-regulated in the presence of B. burgdorferi. These findings suggest different stimuli for MMP induction in untreated and antibiotic-resistant Lyme arthritis.


Sensors and Actuators B-chemical | 2003

Detection of proteins and intact microorganisms using microfabricated flexural plate silicon resonator arrays

Jane Pepper; Richard Noring; Mark S. Klempner; Brian T. Cunningham; Anthony Petrovich; Robert A. Bousquet; Christopher Clapp; Jeanne M. Brady; Brenda Hugh

We are developing biosensor arrays that are based on microfabricated silicon flexural plate wave (FPW) resonators coated with molecular recognition chemistry. The resonators within the micro-chemical analysis array (CANARY) are micro-electromechanical (MEM) sensors that have been miniaturized to allow many independently addressable sensors to be integrated within a single silicon chip. The target analyte of an individual sensor within the chip is selectively detected by depositing molecular recognition component (or “coating”) onto the sensor surface, and monitoring changes in the frequency and phase of the resonance as the coating interacts with the analyte. The ultimate goal of this project is integration of hundreds of miniature resonators within a single chip for detection of biological species. As proof of concept demonstration, we describe here the detection of proteins and intact microorganisms using 2-element and 8-element CANARY sensor chips and address electronics. Preliminary results of sensitivity, selectivity, and surface regeneration methods of the sensor are presented. Detection of proteins and microorganisms with the CANARY sensor were confirmed by optical measurements.


The Journal of Infectious Diseases | 2000

Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease.

Bo Lin; Richard Noring; Allen C. Steere; Mark S. Klempner; Linden T. Hu

Levels of circulating soluble CD14 (sCD14) in patients with various stages of Lyme disease (LD) were examined. Patients with early or untreated late LD had significantly higher levels of sCD14 than did healthy controls (P=.0001 and .0007, respectively); levels returned to normal within 3 months after antibiotic therapy. Patients with persistent posttreatment symptoms of LD had sCD14 levels equivalent to those of healthy controls. Differences in the serum sCD14 levels in patients with various stages of LD are likely to be directly correlated with differences in bacterial burden, suggesting that posttreatment symptoms may not require continued presence of the organism. sCD14 levels in the cerebrospinal fluid (CSF) of patients with any stage of LD were no different from those of control subjects. Levels of synovial fluid sCD14 from patients with Borrelia burgdorferi in their joints were elevated, compared with levels in normal serum, and may play a role in the pathogenesis of arthritis.


The Journal of Infectious Diseases | 1993

Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi.

Mark S. Klempner; Richard Noring; Rick A. Rogers


The Journal of Infectious Diseases | 1995

Binding of Human Plasminogen and Urokinase-Type Plasminogen Activator to the Lyme Disease Spirochete, Borrelia burgdorferi

Mark S. Klempner; Richard Noring; Mark P. Epstein; Bruce McCloud; Rong Hu; Steven A. Limentani; Rick A. Rogers


Blood | 1990

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone : prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects

Gloria Vachino; Mark S. Klempner; Frederick R. Aronson; Richard Noring; Smith S; E P Brandon; Laird W; Michael B. Atkins


Infection and Immunity | 1995

Binding of human plasminogen to Borrelia burgdorferi.

Linden T. Hu; George Perides; Richard Noring; Mark S. Klempner


The American Journal of Medicine | 2001

Intralaboratory reliability of serologic and urine testing for Lyme disease

Mark S. Klempner; Christopher H. Schmid; Linden T. Hu; Allen C. Steere; Gary M. Johnson; Bilaal McCloud; Richard Noring; Arthur Weinstein

Collaboration


Dive into the Richard Noring's collaboration.

Top Co-Authors

Avatar

Mark S. Klempner

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anthony Petrovich

Charles Stark Draper Laboratory

View shared research outputs
Researchain Logo
Decentralizing Knowledge